Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank100
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-2.50
↑ 71% vs avg
Percentile
P100
Near historical high
Streak
1 yr
Consecutive growthElevated
Average
-8.57
Historical baseline
PeriodValueYoY Change
2025-2.50+56.7%
2024-5.76-33.9%
2023-4.31-67.5%
2022-2.57+70.0%
2021-8.56+65.4%
2020-24.72-41.9%
2019-17.42-150.1%
2018-6.97-22.9%
2017-5.67+21.9%
2016-7.26-